exbivirumab
mAbexperimental
Exbivirumab is a human monoclonal antibody developed for the treatment of hepatitis B infections. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 27, 2005 (NCT00228592)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Major surface antigenBINDING AGENT
Major surface antigen binding agent
- Unspecified targetOTHER
Unknown
- Hepatitis B virusImmunity, passive
Hepatitis B virus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaExbivirumab ↗
- ChEMBLCHEMBL2108616 ↗
- ChEMBLCHEMBL2108030 ↗
Also known as
- exbivirumab
- hepex-b
- hepex-b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00228592 | Phase 2 | Sep 27, 2005 | Cubist, Metropolitan Liver Diseases/ Gastroenterology Center |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cubist | For profit | 1 | 1 | 1 | 2005 |
| Metropolitan Liver Diseases/ Gastroenterology Center | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1